
1. Technology overview
aetherAI is a Taiwanese digital pathology and medical imaging AI company founded on 7 October 2015, with its office at Zhongxiao E. Rd., Nangang District, Taipei. According to its about page it raised Series B funding in 2024, listed on Taiwan's Emerging Stock Board, and passed ISO 13485 and ISO 27001.
aetherSlide is a digital pathology system for managing and reviewing pathology images, listed with FDA clearance (K233126), Taiwan FDA approval and CE marking. aetherWeb is a cloud educational platform. Software-only AI products include aetherAI Hema for bone marrow smear analysis and aetherAI Endo for colonoscopy polyp detection. Customers listed include Chang Gung Memorial Hospital, National Taiwan University Hospital and UPMC.
2. Highlighted features & specifications
- aetherSlide: digital pathology system to manage and review slide images.
- aetherWeb: cloud-based digital pathology education platform.
- AI pathology analysis: slide quality control, target region recognition, cell counting and IHC staining quantification.
- aetherAI Hema: bone marrow smear analysis software.
- aetherAI Endo: computer-aided polyp detection for colonoscopy.
- Automated scanning: slide scanning solution with Techman Robot and Hamamatsu Photonics.
3. Potential application
Vietnamese cancer hospitals can digitize pathology slides for remote second opinions with partner hospitals. Pathology labs can use quality control and IHC quantification to standardize reporting. Gastroenterology units can add AI polyp detection to colonoscopy.
4. Benefits
Digitizes pathology slide review with a system that carries FDA, Taiwan FDA and CE regulatory listings. Software-only AI modules integrate with existing imaging equipment, so no new hardware is needed. Used by medical centers in Taiwan, Japan, Europe and the US per the customer list. Automated slide scanning with robot and scanner partners is offered for lab throughput.
5. Market trends & opportunities
Pathologist shortages and rising cancer caseloads are driving digital pathology adoption across Asia. Cancer centers in Vietnam are building digital slide networks for remote consultation, which creates demand for scanners with AI analysis. Taiwanese vendors position themselves as lower-cost alternatives for Southeast Asian laboratories.
6. Other information
Founded October 2015, Taipei. Series B of NT$765 million in 2024 and Emerging Stock Board listing; Taiwan Innovation Board listing application filed December 2025. Entered the Japanese market in 2025. Certifications listed: ISO 13485, ISO 27001, Taiwan FDA device license.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































